8-K: Damora Therapeutics Holds Annual Meeting, Elects Directors

Damora Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of new directors and the ratification of its independent auditor.

Summary

• Damora Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026.
• The meeting addressed four key proposals: election of directors, advisory vote on executive compensation, advisory vote on compensation vote frequency, and ratification of the independent auditor.
• Michael Landsittel and Cameron Turtle, D.Phil were elected as Class III members of the Board of Directors.
• The Say-on-Pay proposal, an advisory vote on executive compensation, was approved.
• A frequency of one year received the plurality of votes for the Say-on-Frequency proposal.
• Ernst & Young LLP was ratified as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A quorum was established with 55,009,938 shares of Common Stock represented out of 60,303,212 outstanding shares as of the April 22, 2026 record date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance activities and expected shareholder outcomes. There are no significant new developments or financial performance indicators presented.

Positives

• Election of two new directors, Michael Landsittel and Cameron Turtle, D.Phil, to the Board.
• Approval of the Say-on-Pay proposal, indicating shareholder confidence in executive compensation practices.
• Ratification of Ernst & Young LLP as the independent auditor, ensuring continued financial oversight.
• A quorum was met, with a significant portion of outstanding shares represented at the meeting.

Future Outlook

The company will hold future Say-on-Pay votes every year until the next required Say-on-Frequency vote, based on the voting results.

Management Comments

• The Board has determined that the Company will hold future Say-on-Pay votes every year until the next required Say-on-Frequency vote.

Industry Context

StockSavvy.ai notes that the outcome of annual meetings, including director elections and auditor ratification, are standard governance procedures for publicly traded companies in the biotechnology sector. Shareholder votes on executive compensation and its frequency are increasingly scrutinized.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Direct impact through voting on director elections, executive compensation, and auditor ratification. The outcome of these votes reflects shareholder sentiment on company management and governance.
• Management: The Say-on-Pay vote outcome provides feedback on executive compensation practices.
• Auditors: Continued engagement with Ernst & Young LLP for fiscal year 2026 provides stability in financial reporting.

Next Steps

• Hold future Say-on-Pay votes annually.
• Michael Landsittel and Cameron Turtle, D.Phil will serve as Class III Directors until the 2029 Annual Meeting of Stockholders.

Key Dates

Keywords

Damora Therapeutics, Annual Meeting, Board of Directors, Executive Compensation, Independent Auditor, Stockholder Vote, Corporate Governance, SEC Filing